Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: New section on PTSC's website

My interpretation is totally positive. I read it as an increase in DS/SS revenues as opposed as a decrease in MMP revenues.

~2/3 revenues from DS/SS and ~1/3 from MMP. Let say PTSC matches 2008 MMP revenues of 19.9MM which is ~1/3 of the pie and DS/SS revenue targets are reached, then total revenue is ~60MM.

There are multiple mentions of expanded MMP licenses as continued growth for investment capital. The charts represents the transformation from the former PTSC to the new PTSC in which the former company was totally dependent on MMP licenses for revenue to the new company in which the MMP is certainly not the main mast. The vision is that PTSC becomes a company that generates revenues in proportions that would portray the MMP as mere lagniappe.

Regards,
PxP



Share
New Message
Please login to post a reply